正在加载视频...

视频加载失败

Here is an excellent answer for a question which I’m asked a lot - could there be a viable business model for a “one & done” Gene Therapy treatment and for CRISPR companies such as $PRME, $BEAM, $LLY, $NTLA, $CRSP, $CRBU, $MGX, $LCTX, $SANA and more. During his excellent...

191,202 次观看 • 9 天前 •via X (Twitter)

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

$PLTR Some of the commenters under this clip on YouTube were trying to understand what Dr. Karp was talking about because they didn't get the full context. OpenAI and Anthropic recently started working with a bunch of PE firms to create "Deployment Companies." These companies copied Palantir's FDE (Forward Deployed Engineer) model to dispatch people or teams to businesses and help build products for those companies to make them more "efficient." Karp is saying that a lot of these products are being made not for the benefit of the client, but for the benefit of the model providers, as they burn through tokens and thus cost an arm and leg without real long term tangible benefits. Karp's reasoning, in my opinion, is pretty sound. I think the creation of this "Deployment Company" concept is sort of a Trojan horse: many of the portfolio companies might initially find it interesting, but they will ultimately have to deal with runaway costs, inconsistent support, and, most of all, trust issues that cant be won overnight. When I first saw this, I thought it might be a threat to Palantir, but looking back... I think this is a desperate attempt by the model companies to generate some additional high-margin enterprise revenue before the IPO and roadshow. A lot of the private equity companies have exposure to OpenAI and Anthropic through credit investments for the data center build-out, and cannot afford to have these companies drop in value. They thus have no choice but to leverage their existing portfolio companies to adopt these "Deployment" companies. Would love to hear your thoughts Eliano A Younes Chad Wahlquist

Kris Patel 🇺🇸

17,575 次观看 • 1 个月前